Mark Koh, MD, on Pathology, Genetics, and Global Collaboration in Pediatric Dermatology
At the recent 2026 Society for Pediatric Dermatology Annual Meeting, Mark Koh, MD, provided critical updates on the management of pediatric histiocytosis. His presentation highlighted how recent discoveries regarding BRAF and MEK pathway mutations have shifted the medical community toward targeted molecular treatments for conditions like Langerhans cell histiocytosis. This progress underscores the importance of integrating advanced genetics into standard clinical practice to improve patient outcomes.
Beyond current treatment strategies, Dr. Koh addressed the enduring necessity of dermatopathology in pediatric care. He demonstrated that while molecular testing is powerful, histopathologic evaluation remains essential for accurate diagnosis. In many instances, the physical skin biopsy acts as the primary tool to reconcile clinical findings or clarify ambiguous cases. He noted that even basic diagnostic methods, such as hair mount examinations for conditions like alopecia areata, continue to serve as vital components in a clinician's toolkit.
Dr. Koh also serves as the secretary of the International Society of Pediatric Dermatology and president of the Asian Society of Pediatric Dermatology. In these roles, he is pushing for greater global cooperation. By offering free membership and shared educational resources, these organizations aim to connect specialists across North America, Europe, and Asia. This effort focuses on improving standards of care in underserved regions through better communication and shared expertise among pediatric dermatologists.
The discussions at the 2026 conference represent a significant move toward precision medicine in childhood skin disease. As genetic testing becomes more accessible, the collaboration between dermatologists and pathologists is increasingly important for managing complex pediatric dermatoses. These updates signal a broader trend in the field toward combining molecular science with traditional clinical assessment to treat rare disorders more effectively.